Drugs and patents in ATC class N04BX - Other dopaminergic agents

Q: 4) How do method-of-use patents in Parkinsonâ€™s dopaminergic therapies block label design-around?

If the genericâ€™s proposed label and dosing regimen align with the protected method claims, non-infringement is harder. Courts also focus on claim construction and how the product is used in practice.

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
TASMAR	tolcapone
TOLCAPONE	tolcapone
CARBIDOPA, LEVODOPA AND ENTACAPONE	carbidopa; entacapone; levodopa
STALEVO 100	carbidopa; entacapone; levodopa
>Tradename	>Generic Name

Last updated: July 6, 2026

ATC class N04BX covers “Other dopaminergic agents,” a residual bucket that includes dopamine-pathway molecules and formulations not classified elsewhere under N04. The patent landscape is therefore fragmented: exclusivity and litigation risk concentrate in specific drugs inside N04BX (not the class as a whole), with additional protection layered through formulation, polymorph, and method-of-use patents.

This report maps market dynamics, typical IP fences that matter for entry, and the procedural and regulatory pathways that determine whether challengers can launch with FDA approvals (or EU market authorizations) before key patents expire.

What drugs are in ATC N04BX and how does the patent landscape differ across them?

Answer: N04BX is not a single active ingredient. The patent estate and exclusivity timeline are drug-specific. In practice, investors and litigators treat N04BX as a portfolio of product-level patent tracks where the strongest protection often comes from late-cycle formulation and dosing patents, not early composition-of-matter.

Subcategory mapping: where N04BX risk concentrates

N04BX includes “other dopaminergic agents,” and the patent-driven risk typically concentrates in:

Adjunct dopaminergic therapies for Parkinson’s disease symptoms (or related movement-disorder endpoints).
Agents affecting dopamine signaling via receptor modulation, dopamine precursor pathways, or downstream dopaminergic effects.
Products with complex delivery (extended-release, combination tablets/capsules, or special coating/manufacturing).

In these products, the IP portfolio usually shows four layers:

Composition or salt form (early filings; earliest expirations).
Polymorph/crystal form or specific solid-state parameters.
Formulation and dosage regimen (late filings; block “switching”).
Method-of-use / patient subset / titration regimen (litigation leverage for design-arounds).

How the “residual class” complicates freedom-to-operate (FTO)

Because N04BX is a bucket, an FTO search cannot rely on class-based clearance. Instead, it must track:

exact INN/brand,
route of administration and dosage form,
label claims tied to method-of-use patents,
jurisdiction-specific filing and prosecution differences (EP vs US vs JP vs KR).

How strong is the patent estate for N04BX dopaminergic products?

Answer: In this category, the patent estate is typically strongest where the product has (i) special delivery/formulation and (ii) label-specific use tied to dopamine-pathway mechanism.

Patent types that most often block generic entry

For N04BX-like products, the most litigation-relevant patent classes are:

Formulation patents
- controlled-release matrices,
- coated multipart pellets/tablets,
- release kinetics tied to specific in vitro dissolution profiles.
Solid-state patents
- polymorphs,
- solvates/hydrates,
- particle-size distributions and milling processes.
Process/manufacturing patents
- steps that affect final release rate, viscosity, or stability,
- impurity profiles and controlled recrystallization.
Method-of-use patents
- initiation/titration regimen,
- symptom subtypes (e.g., “off” time reduction),
- adjunct use alongside levodopa.

Common design-around paths and why they often fail

Generic sponsors often attempt:

salt swaps,
alternate polymorph targets,
changed release profiles,
alternative dosing schedules.

In dopaminergic symptom therapies, method-of-use patents and formulation patents can still catch challengers because litigation focuses on whether the ANDA/SNDA product is “within the scope” of claims by therapeutic function, release profile, or specific dosing.

When does exclusivity end for N04BX drugs, and what drives the effective “last day to launch”?

Answer: The effective launch window is driven by the overlap of:

US regulatory exclusivities (where applicable),
Orange Book patent expirations (composition and formulation),
regulatory exclusivity tied to exclusivity periods (3, 5, or 7 years depending on pathway and exclusivity category),
and patent term adjustments or extensions that shift real expiry dates.

Timeline structure used in N04BX entry planning

For each N04BX product, the “last day” usually follows this chain:

Early composition/salt expiry
Typically earliest in the portfolio; may not be decisive if later patents remain.
Later formulation/polymorph expiry
Often the real bottleneck; can be 5 to 15 years after earliest filings depending on claim sets and continuation strategy.
Method-of-use expiry
Can be later than composition if separate application families exist.
FDA exclusivity (if still active)
- blocks approval of an ANDA for a period even if patent barriers are cleared (context-dependent).
Litigation stays / injunctions
- can delay “day one” even after expiration depending on settlement or court rulings.

What is the Orange Book status of N04BX products and which patents block ANDA launches?

Answer: The Orange Book is usually where the operational blockers are identified: listed patents map to ANDA/SNDA eligibility and Paragraph IV/II submissions.

How to read Orange Book listings for N04BX programs

Identify whether the Orange Book lists patents under:
- Drug substance,
- Drug product,
- Method of use.
In dopaminergic agents, method-of-use and drug-product patents are the most likely to create “practical” barriers even when composition patents are expired.

What “blocks entry” in litigation

For N04BX-like products, the high-impact patents are typically:

those tied to release characteristics or formulation parameters,
those tied to specific therapeutic outcomes (endpoint claims),
those tied to solid-state forms that preserve stability and bioavailability.

Which patents are typically challenged via Paragraph IV for dopaminergic products in N04BX?

Answer: Paragraph IV challengers generally target:

late-expiring formulation patents,
solid-state/polymorph patents that are difficult to design around without changing the claimed product class,
and method-of-use patents where the challenger can argue non-infringement or invalidity based on claim scope.

Typical Paragraph IV targets

For N04BX-style programs:

Device-free oral extended-release formulations often draw patent challenges focused on equivalence in release kinetics.
Polymorph and solid-state patents draw challenges centered on whether an alternative crystalline form avoids infringement.
Titration or regimen patents invite challenges based on the proposed generic’s label and actual dosing schedule.

Settlement patterns that matter commercially

When Paragraph IV litigation settles, the economic effect often arrives through:

payment-for-delay style settlements (US) where allowed,
carve-outs excluding certain formulations/dosing schedules,
or launch-date covenants that fix an entry date despite partial claim clearance.

What patent litigation affects N04BX dopaminergic agents and how does it change generic launch risk?

Answer: Litigation affects launch risk through:

injunction leverage,
settlement dates,
and the time needed for court outcomes that can override expiration-based planning.

Litigation “hot spots” in this therapeutic area

Across dopaminergic therapies, litigation clusters around:

drug-product patents for controlled-release versions,
method-of-use patents for symptom control claims,
and solid-state patents for stability.

Business consequence for entrants

Even if a challenger designs around composition patents, continued litigation on:

formulation scope,
method-of-use interpretation,
or process-specific claims can extend “no-approval” periods via court stays and settlement.

How does N04BX compare with other Parkinson’s-related ATC classes in terms of IP intensity and generic entry?

Answer: N04BX generally shows higher IP intensity per branded product when the products in the bucket use complex formulations or label-specific endpoints, which are common in modern Parkinson’s symptom management.

Comparison to other N04 buckets (high-level)

Classes with “simple” immediate-release small molecules usually see earlier generic entry because fewer formulation/polymorph claims survive.
Classes with controlled-release technologies and dopamine-pathway endpoint claims often see delayed entry due to formulation and method-of-use patent layering.

Practical takeaway: the generic timeline in N04BX is typically driven by product-specific formulation IP, not by the fact that the drug is dopaminergic.

What formulation and manufacturing patents protect N04BX products?

Answer: Protection most commonly covers:

extended-release matrices and coated multipart systems,
manufacturing steps affecting particle size, uniformity, and dissolution,
and solid-state properties that preserve stability and bioavailability.

Patent claim patterns seen in controlled dopaminergic products

Common motifs:

“A composition comprising” plus specific ratios and excipients that achieve a dissolution and absorption profile.
“A method for manufacturing” with specific parameters for mixing, granulation, drying, or coating.
“A crystalline form” identified by diffraction/thermal properties.

Why manufacturing patents create “entry barriers” even when chemical identity is known

A generic may match chemical identity but fail equivalence if:

release kinetics differ,
impurity profiles exceed thresholds,
or the method-specific manufacturing steps are embedded in claims.

What method-of-use patents exist for dopaminergic agents in N04BX, and when do they expire?

Answer: Method-of-use patents typically cover:

symptom reduction endpoints,
adjunct or add-on use with levodopa,
and dosing regimen features (titration, timing relative to meals, and management of “off” periods).

How method-of-use patents change design-around strategies

Generic sponsors often prefer to pursue:

a label that avoids protected claims,
or non-infringement arguments based on claim construction.

But if the formulation is engineered to meet the same therapeutic endpoint, and the label aligns with the protected regimen, method-of-use patents can still block or extend litigation.

Which companies dominate N04BX commercialization, and what does that imply for licensing and exclusivity?

Answer: Dominant positions typically sit with originator pharma companies that built the formulation and solid-state portfolio. Licensing and settlements usually involve:

large generics with technical capacity for controlled-release and solid-state matching,
or specialty players targeting lifecycle management and incremental product versions.

How originators monetize late-cycle IP

Originators monetize via:

continuations that extend formulation/polymorph coverage,
label expansions that increase method-of-use coverage,
and jurisdictional continuation that pushes out local expiry.

What generic entry risks exist for N04BX products?

Answer: The major entry risks are:

Patent infringement risk on formulation/solid-state claims.
Regulatory pathway risk if FDA exclusivity blocks approval.
Litigation risk if court stays or injunctions persist.
Design-around risk if “equivalents” in release profile or therapeutic effect still fall within claim scope.

High-risk scenario archetypes

Controlled-release products where formulation patents remain unexpired.
Solid-state products where the alternative polymorph is not fully equivalent for dissolution and stability.
Products where method-of-use claims track the most clinically used indication or add-on regimen.

What are the geographic differences in patent enforcement for N04BX dopaminergic agents?

Answer: Differences arise from:

early filing strategy (EP vs national),
patent term and adjustment frameworks,
and litigation access and injunction practices.

Typical enforcement map for dopaminergic lifecycle

US: strong emphasis on Orange Book listing, Paragraph IV, and district court outcomes.
EU: enforcement through national courts with EP validity and claim interpretation critical.
UK: post-Brexit enforcement remains via national frameworks.
Japan and Korea: strong local practice for invalidity and infringement, which affects generic strategy.

For market entry, “global readiness” requires mapping claim status and enforceability country by country.

Key tables for N04BX IP tracking (what to compile for every product)

Because N04BX is a residual ATC bucket, the operational requirement is product-by-product compilation.

Table: Product-level IP watchlist schema (use for each N04BX drug)

Field	What to capture	Why it matters
Active ingredient / brand	Exact INN and brand(s)	Determines which Orange Book entries and patent families apply
Dosage form	IR vs ER, tablets vs capsules vs patches	Determines whether formulation patents block entry
Listed Orange Book patents	Drug substance / drug product / method of use	Sets Paragraph IV targets and litigation blockers
Filing and priority dates	Earliest effective filing family dates	Predicts base patent expiry and continuations
Patent term and adjustments	PTA/PTE where applicable	Shifts expiry beyond basic term
Exclusivity periods	Regulatory exclusivity type	Blocks ANDA/SNDA approvals independent of patent expiry
Litigation dates	Filing date, first motions, claim construction, verdict	Determines whether settlement likely
Settlement triggers	Launch-date covenants and carve-outs	Fixes business timing and product scope

Key Takeaways

N04BX is not a unified IP landscape; it is a basket where product-level formulation and method-of-use patents drive entry delay.
Exclusivity and Orange Book listings usually determine whether challengers can launch, but formulation/solid-state and method-of-use patents determine whether they can practically sustain non-infringement positions.
The dominant commercial risk for generics in N04BX is not early composition expiry. It is late-cycle product protection paired with litigation and settlement-based launch timing.
Competitive advantage for originators depends on controlled-release/formulation mastery and label-linked method-of-use claim coverage across jurisdictions.

FAQs

1) What patents protect controlled-release dopaminergic formulations in N04BX?

Controlled-release dopaminergic products typically rely on drug-product patents covering matrix/coating design, dissolution profile targets, and manufacturing steps that preserve release kinetics, plus solid-state patents for stability.

2) When do N04BX dopaminergic drugs lose regulatory exclusivity for generic approvals?

Loss of regulatory exclusivity is product- and pathway-specific. In practice, it must be checked alongside Orange Book patent expiry because patent status can still block approval even after exclusivity ends.

3) What is the typical settlement structure in Paragraph IV litigation for dopaminergic products?

Settlements often include launch-date covenants, potential formulation carve-outs, and dismissal of claims in exchange for fixed timing commitments that override generic-ready planning.

4) How do method-of-use patents in Parkinson’s dopaminergic therapies block label design-around?

If the generic’s proposed label and dosing regimen align with the protected method claims, non-infringement is harder. Courts also focus on claim construction and how the product is used in practice.

5) Which jurisdictions present the highest enforcement leverage for N04BX dopaminergic agents?

Enforcement leverage is usually highest where injunction practices and local court timelines are most favorable to patent owners and where EP/national claim validity aligns cleanly with the enforced product.

References

FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
EMA. European public assessment reports and product information for centrally authorized medicines. European Medicines Agency.
FDA. 21 CFR Part 314 (Approved New Drug Applications and Abbreviated New Drug Applications). U.S. Food and Drug Administration.